Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Post-marketing surveillance study in Japan evaluating Calquence (acalabrutinib) as first-line therapy for previously untreated chronic lymph…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial update evaluating venetoclax in combination with ibrutinib for chronic lymphocytic leukemia and small lymphocytic lym…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi [Phase 2]
This clinical trial update describes a Phase 2 study evaluating pirtobrutinib in combination with venetoclax for patients with chronic lymph…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia [Phase 2]
This is a Phase 2 clinical trial update on acalabrutinib combined with venetoclax or obinutuzumab for treatment-naive chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
A Phase 3 clinical trial comparing acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphoc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
EMA approval · 2026-02-17EMA Authorised: Imbruvica (Ibrutinib) — Janssen-Cilag International NV
EMA authorised Imbruvica (ibrutinib) for mantle cell lymphoma and chronic lymphocytic leukemia, with Janssen-Cilag International NV as the m…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome [Phase 1]
Phase 1 clinical trial update evaluating epcoritamab in chronic lymphocytic leukemia and Richter syndrome. The study is currently active but…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome [Phase 2]
Phase 2 clinical trial evaluating a triple-drug regimen (atezolizumab, obinutuzumab, and venetoclax) for chronic lymphocytic leukemia, small…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets [Phase 1]
This clinical trial update describes the ongoing Phase 1 study of ABBV-525 tablets in adults with B-cell malignancies. The study evaluates a…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial update examining the combination of pirtobrutinib and venetoclax with measurable residual disease (MRD) detection for…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Dana-Farber Cancer Institute-led clinical study recruiting to investigate molecular progression and clinical outcomes in MGUS, smoldering …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study evaluating roginolisib (IOA-244) in combination with venetoclax and rituximab for patie…
-
CLINICAL_TRIALS other · 2026-02-11Clinical Trial Update: Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
An Emory University-sponsored clinical trial is recruiting to evaluate human immune responses to vaccination in patients with lymphoma. The …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
This clinical trial update notes a Phase 2 study of acalabrutinib with or without obinutuzumab in patients with early-stage chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase 2 clinical trial evaluating the combination of oral venetoclax and intravenous obinutuzumab in adults with recurring chronic lymphoc…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of PRGN-3007 UltraCAR-T cells in patients with advanced hematologic and solid tumors has complet…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL [Phase 1]
Phase 1 study evaluating CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; th…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations [Phase 2]
This is a Phase 2 clinical trial update assessing the combination of venetoclax and ibrutinib in participants with chronic lymphocytic leuke…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial is evaluating whether adding venetoclax to the standard combination of ibrutinib and obinutuzumab improves outcomes in untre…